Obstructive Laryngitis Treatment Market Report 2024

This Obstructive Laryngitis Treatment market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The obstructive laryngitis treatment market size has grown strongly in recent years. It will grow from $1.85 billion in 2023 to $1.95 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be attributed to several factors, including the increasing incidence of conditions such as vocal cord paralysis, a heightened demand for effective treatment options, a rise in respiratory and laryngeal disorders, advancements in telemedicine, and greater awareness and utilization of voice therapy.

The obstructive laryngitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.44 billion in 2028 at a compound annual growth rate (CAGR) of 5.7%. The growth during the forecast period can be attributed to a higher demand for treatment options, increasing incidences of bacterial and viral infections, an expanding aging population, greater exposure to harmful chemicals, and rising healthcare expenditure. Key trends expected during this period include advancements in technology, the integration of telemedicine, the development of biologic therapies, improvements in diagnostic imaging, and the application of machine learning.

The growth of the obstructive laryngitis treatment market is expected to be driven by the rising incidence of bacterial and viral infections. These infections, caused by microorganisms such as bacteria and viruses, invade the body, reproduce, and disrupt normal bodily functions. Factors contributing to the increasing incidence of these infections include more global travel, climate change, and antibiotic resistance. Treatment for obstructive laryngitis typically involves antibiotics and corticosteroids to eliminate pathogens and reduce inflammation, while viral infections are managed with symptomatic treatments, corticosteroids for severe inflammation, and supportive care such as voice rest and hydration. For example, in November 2023, the World Health Organization (WHO) estimated that there would be around 10.6 million cases of tuberculosis (TB) globally in 2022, impacting 5.8 million men, 3.5 million women, and 1.3 million children. This rising incidence of bacterial and viral infections is fueling growth in the obstructive laryngitis treatment market.

Leading companies in the obstructive laryngitis treatment market are concentrating on developing innovative solutions, such as chewable tablets, to prevent acid from escaping into the esophagus, thereby relieving pain and discomfort. A chewable tablet is a solid form of medication designed to be chewed before swallowing, promoting easier ingestion and quicker absorption. For example, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based manufacturing company, launched a chewable anti-reflux antacid tablet containing sodium alginate and potassium bicarbonate. This chewable tablet is primarily used to treat acid reflux and gastroesophageal reflux disease (GERD). In the context of laryngitis treatment, it helps reduce irritation in the larynx caused by acid reflux, which can contribute to or worsen laryngitis. By forming a protective barrier in the stomach, the tablet prevents acid from rising into the esophagus and throat, easing symptoms such as throat irritation and inflammation that can worsen laryngitis.

In February 2024, GSK plc, a UK-based pharmaceutical and biotechnology company that develops and manufactures vaccines and specialty medicines to prevent and treat disease, acquired Aiolos Bio, Inc. for an undisclosed amount. The acquisition enhances GSK's respiratory portfolio by integrating AIO-001, a long-acting anti-lymphopoietin monoclonal antibody that targets unmet needs in asthma treatment, particularly for patients with low T2 inflammation where current options are limited. Aiolos Bio, Inc. is a UK-based biotechnology company that focuses on developing treatments for respiratory and inflammatory conditions.

Major companies operating in the obstructive laryngitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Macleods Pharmaceuticals Limited, Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Mankind Pharma Limited, Unichem Laboratories Limited, Mylan N.V., Strides Pharma Science Limited, USV Private Limited.

North America was the largest region in the obstructive laryngitis treatment market in 2023. The regions covered in the obstructive laryngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the obstructive laryngitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Obstructive laryngitis treatment involves medical methods to manage inflammation and obstruction of the larynx (voice box), which affects breathing and vocal function. This treatment aims to relieve symptoms such as hoarseness, breathing difficulties, and throat discomfort, while also reducing inflammation and clearing the obstruction.

The primary medications used for obstructive laryngitis include glucocorticoids, dexamethasone, and epinephrine. Glucocorticoids, a type of steroid medication, help reduce inflammation and swelling in the throat for patients with obstructive laryngitis. These medications can be administered through various routes, including oral and intravenous, and are available through different distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The obstructive laryngitis treatment market research report is one of a series of new reports that provides obstructive laryngitis treatment market statistics, including obstructive laryngitis treatment industry global market size, regional shares, competitors with an obstructive laryngitis treatment market share, detailed obstructive laryngitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the obstructive laryngitis treatment industry. This obstructive laryngitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The obstructive laryngitis treatment market includes revenues earned by entities by providing services such as pharmacological treatments, voice therapy, medical monitoring and diagnostics, and surgical interventions and related corticosteroid medications, antibiotics, antihistamines, and nasal sprays. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.